• No results found

Data quality indices for population-based survival study

5. RESULTS

5.2 Data quality indices for population-based survival study

The comparison of descriptive statistics on data quality indices of population-based cancer

survival for lung and breast cancers between selected registries classified on methods of

cancer registration and follow up are given in Table 5 (SURVCAN).

Table 5: Data quality indices: Frequency of excluded cases expressed as proportion of death certificate only and no follow up cases for lung and breast cancers in selected registries from low or medium resource countries separately for passive and active methods of cancer registration and follow up, 1990-2001* (SURVCAN database)

Lung Breast

Country/Registry Total registered

DCO% NFU% Included %

Total registered

DCO% NFU% Included % Passive methods of

registration and follow up

China, Shanghai 14,113 0.0 0.1 99.9 5,184 0.0 0.0 100.0

Costa Rica DNA DNA DNA DNA 2,854 2.5 11.2 86.3

Korea, Seoul 10,294 12.7 4.9 82.4 5,907 3.3 6.0 90.7 Thailand, Lampang 3,278 7.8 0.3 91.9 842 1.4 0.0 98.6 Range 0-13 0-5 82-100 0-3 0-11 86-100 Active methods of registration and follow up China, Qidong 3,303 0.3 0.4 99.3 669 0.3 2.4 97.3 India, Barshi 48 2.1 0.0 97.9 124 0.0 0.0 100.0 India, Mumbai 3,995 13.0 0.6 86.4 7751 5.2 0.7 94.1 Thailand, Songkhla 850 5.1 16.1 78.8 665 1.2 13.3 84.5 Range 0-13 0-16 79-99 0-5 0-13 85-100

DCO: Death certificate only; NFU: No follow up; DNA: Data not available * Period varies for individual registries

The figures for frequency of lung cancer cases included for survival analysis ranged

between 82-100% for selected registries in Asia and Central America, employing passive

methods and 79-99% for selected registries in Asia undertaking active methods (Table 5).

The corresponding figures for breast cancer were 86-100% and 85-100% respectively. The

range of DCOs for lung cancer was 0-13% in both groups of registries; the range for no

follow up cases was 0-5% in registries with passive methods and 0-16% in registries with

active methods for lung cancer. The range of DCOs for breast cancer was 0-3% in registries

with passive methods and 0-5% in registries with active methods; the corresponding figures

for no follow up cases were 0-11% and 0-13% respectively. The comparison of frequency of

cases included for survival analysis out of total incident cases between the two groups of

registries that pursued passive or active methods of case registration and follow up revealed

minimal variation for lung and breast cancers (Table 5). This augurs well for the conduct of a

population-based cancer survival study.

However, the frequency of cancer cases excluded from survival study (owing to being

DCOs or no follow up (NFU) with zero survival time) and the frequency of cases with

incomplete or loss to follow up (LFU) among cases included in survival study both have to be

considered in unison to evaluate data quality in population-based survival study. There may

be instances when one is minimal while the other is not. The following scenarios from real

data present the different problems encountered pertaining to data quality indices and

Table 6: Frequency of cases registered as DCO or with lack of complete follow up for common cancers in Cuba, 1994-1995 followed through 1999*

Excluded from survival study

Incomplete follow up: % lost to follow up- years from diagnosis

Cancer/site Total

registered DCO% NFU%

Included in analysis % Complete follow up % <1 1-3 3-5 >5 Tongue 314 25.5 0.9 73.6 95.2 3.0 0.9 0.9 0.0 Mouth 355 25.9 0.9 73.2 93.4 3.1 1.9 1.2 0.4 Tonsil 82 32.9 1.2 65.9 98.1 0.0 0.0 1.9 0.0 Oropharynx 60 20.0 0.0 80.0 97.9 2.1 0.0 0.0 0.0 Colon 2491 49.7 0.2 50.1 99.2 0.2 0.2 0.3 0.1 Rectum 790 29.1 0.5 70.4 98.0 1.1 0.4 0.5 0.0 Anus 106 8.5 2.8 88.7 98.9 1.1 0.0 0.0 0.0 Larynx 1165 30.7 0.6 68.7 96.3 1.5 0.9 1.0 0.3 Breast 2929 25.6 0.3 74.1 97.0 0.9 0.3 1.4 0.4 Cervix uteri 1450 15.4 0.4 84.2 94.4 2.2 1.2 1.7 0.5 Urinary bladder 1182 29.5 1.2 69.3 97.4 1.2 0.0 1.0 0.4 Hodgkin lymphoma 320 40.3 1.6 58.1 97.4 1.6 0.5 0.5 0.0

Non Hodgkin lymphoma 771 39.7 0.1 60.2 97.7 0.6 0.6 1.1 0.0

DCO: Death certificate only; NFU: No follow up or lost to follow up with zero survival time; * SURVCAN database

Table 6 shows the frequencies of cases pertaining to all the data quality indices of

population-based survival for selected cancers in Cuba during 1994-1995 and followed

through 1999 (SURVCAN). Registration of cancer cases was carried out entirely by passive

method. The frequency of cases registered as DCO ranges between 9-50% for different

cancers. The very high figure may be the result of lack of active method of tracing back the

cancer cases, first identified through a death certificate, to hospitals or to other sources of

registration. On the other hand, the frequency of cases with zero survival time and vital status

unknown were negligible ranging between 0-3%. In total, the frequency of cases included for

survival analysis ranged between 50-89%. This is quite low and may or may not be a random

sample or representative of the total incident cases. On the other hand, among the cases

included for survival analysis, the complete follow up was achieved in 94-99%, which is

adequate (Table 6). Follow up for vital status information was carried out predominantly by

passive methods with minimal active component. Overall, despite good follow up, the

resulting survival may not reflect the average outcome of respective cancers in the region

owing to high degree of exclusion from the survival study thereby indicating high selection of

cases.

The other kind of problem pertaining to inadequate follow up usually encountered in

Table 7: Frequency of cases registered as DCO or with lack of complete follow up for common cancers in Khon Kaen, Thailand, 1993-1997 followed through 2000*

Excluded from survival study

Incomplete follow up: % lost to follow up- years from diagnosis

Cancer/site Total

registered DCO% NFU%

Included in analysis % Complete follow up % <1 1-3 3-5 >5 Lip 88 1.1 9.1 89.8 67.1 19.0 5.1 6.3 2.5 Tongue 57 0.0 5.3 94.7 77.8 20.3 1.9 0.0 0.0 Mouth 120 3.3 7.5 89.2 73.8 19.6 2.8 1.9 1.9 Nasopharynx 123 0.0 4.1 95.9 80.5 12.8 4.2 0.8 1.7 Colon 258 1.6 4.7 93.8 79.8 6.6 6.2 5.4 2.0 Rectum 143 0.0 2.8 97.2 80.6 10.1 6.5 0.7 2.1 Larynx 38 0.0 5.3 94.7 80.6 19.4 0.0 0.0 0.0 Breast 446 1.1 5.2 93.7 41.4 24.4 22.2 7.7 4.3 Ovary 230 0.9 9.6 89.6 47.1 28.6 12.6 8.7 3.0 Urinary bladder 114 0.0 9.6 90.4 41.7 35.9 10.7 8.7 3.0 Hodgkin lymphoma 31 0.0 6.5 93.5 37.9 27.6 17.2 6.9 10.4

Non Hodgkin lymphoma 191 0.0 12.0 88.0 53.0 28.0 10.1 6.0 2.9

DCO: Death certificate only; NFU: No follow up or lost to follow up with zero survival time; * SURVCAN database

Table 7 describes both the two data quality indices pertaining to cancer registration

and follow up as observed in survival data from Khon Kaen, Thailand, in 1993-1997 and

followed through 2000. Both cancer registration and follow up were carried out

predominantly by active methods. The frequency of cases registered as DCO was minimal

ranging between 0-3% for different cancers. This possibly is due to trace-back procedures by

active methods adopted by the registry. However, the frequency of cases excluded from

survival study with zero survival time and vital status unknown was higher ranging between

3-12%. In total, the frequency of cases included for survival analysis ranged between 88-

97%, which is satisfactory. Among the cases included for survival analysis, the complete

follow up was achieved only in 38-81% for different cancers. Overall, despite minimal

exclusions from the study, the resulting absolute survival is not likely to reflect the average

outcome of respective cancers in the region owing to the very high degree of incomplete or

losses to follow up (19-62%), especially due to high losses to follow up within the first year

from diagnosis (7-36%). These data quality indices, with the exception of DCOs, are

applicable to hospital-based survival studies also.

Related documents